Advertisement
Advertisement
U.S. Markets open in 1 hr 25 mins
S&P Futures
4,083.00 -7.00 (-0.17%) Dow Futures
34,044.00 -112.00 (-0.33%) Nasdaq Futures
12,151.75 -0.25 (-0.00%) Russell 2000 Futures
1,936.70 -2.70 (-0.14%) Crude Oil
79.23 +0.36 (+0.46%) Gold
1,945.40 +0.10 (+0.01%)
Minerva Neurosciences, Inc. (NERV)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
Pre-Market:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 2.3200 |
| Open | 2.3700 |
| Bid | 2.3900 x 3100 |
| Ask | 2.4900 x 1100 |
| Day's Range | 2.3500 - 2.3900 |
| 52 Week Range | 1.2600 - 15.2700 |
| Volume | |
| Avg. Volume | 165,608 |
| Market Cap | 102.105M |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | 49.79 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
- American City Business Journals
The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application
The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish.
- Zacks
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
